Rivastigmine for Alzheimer’s disease

References

• Finkel SI, Costa e Silva J, Cohen G, Miller S, Sartorius N. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int. Psychogeriatr. 8(Suppl. 3), 215–552 (1996).
   PubMedGoogle Scholar
• Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 288, 1475–1483 (2002).
   PubMed Web of Science ®Google Scholar
• Mayeux R, Sano M. Treatment of Alzheimer’s disease. N. Engl. J. Med. 341, 1670–1679 (1999).
   PubMed Web of Science ®Google Scholar
• Seshadri S, Wolf PA, Beiser A et al. Lifetime risk of dementia and Alzheimer’s disease: the impact of mortality on risk estimates in the Framingham Study. Neurology 49, 1498–1504 (1997).
   PubMed Web of Science ®Google Scholar
• Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am. J. Epidemiol. 154, 635–641 (2001).
   PubMed Web of Science ®Google Scholar
• Bachman DL, Wolf PA, Linn RT et al. Incidence of dementia and probable Alzheimer’s disease in a general population – the Framingham Study. Neurology 43, 515–519 (1993).
   PubMed Web of Science ®Google Scholar
• Fillit HM. The pharmacoeconomics of Alzheimer’s disease. Am. J. Manag. Care 6(Suppl. 22), S1139–S1144 (2000).
   PubMedGoogle Scholar
• Dickson TC, Vickers JC. The morphological phenotype of β-amyloid plaques and associated neuritic changes in Alzheimer’s disease. Neuroscience 105, 99–107 (2001).
   PubMed Web of Science ®Google Scholar
• Torre JC. Is Alzheimer’s disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 3, 184–190 (2004).
   PubMedGoogle Scholar
• Desai AK, Grossberg GT. Current concepts in the diagnosis and treatment of Alzheimer’s disease. Neurology 64(Suppl. 3), S34-S39 (2005).
   PubMedGoogle Scholar
• Terry AV Jr, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer’s disease – related cognitive deficits: recent challenges and their implications for novel drug development. J. Pharmacol. Exp. Ther. 306(3), 821–827 (2003).
   PubMed Web of Science ®Google Scholar
• Kihara T, Shimmohama S. Alzheimer’s disease and acetylcholine receptors. Acta. Neurobiol. Exp. 64, 99–105 (2004).
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Kaufer DI, Hendrickson R et al. Cognitive correlates of alterations in acetylcholinesterase in Alzheimer’s disease. Neurosci. Lett. 380(1–2), 127–132 (2005).
   PubMed Web of Science ®Google Scholar
• Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 66, 137–147 (1999).
   PubMed Web of Science ®Google Scholar
• Lemstra AW, Eikelenboom P, van Gool WA. The cholinergic deficiency syndrome and its therapeutic implications. Gerontology 49, 55–60 (2003).
   PubMedGoogle Scholar
• Morris JC. Mild cognitive impairment and preclinical Alzheimer’s disease. Geriatrics (Suppl.1), 9–14 (2005).
   PubMedGoogle Scholar
• Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56, 303–308 (1999).
   PubMed Web of Science ®Google Scholar
• Ikonomovic MD, Mufson EJ, Wuu J, Bennett DA, Dekosky ST. Reduction of choline acetyltransferase activity in primary visual cortex in mild to moderate Alzheimer’s disease. Arch. Neurol. 62(3), 425–430 (2005).
   PubMedGoogle Scholar
• Jean JC, Davis RE. Cholinergic therapies for Alzheimer’s disease; acetylcholinesterase inhibitors of current clinical interest. Curr. Opin. Invest. Drug 2, 363–377 (1993).
   Google Scholar
• Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA 271, 992–998 (1994).
   PubMed Web of Science ®Google Scholar
• Geldmacher DS. Donepezil (Aricept) for treatment of Alzheimer’s disease and other dementing conditions. Expert Rev. Neurotherapeutics 4(1), 5–16, (2004).
   PubMedGoogle Scholar
• Birks JS, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer’s disease (Cochrane review). In: The Cochrane Library, Issue I. Update Software, Oxford, UK (2001).
   Google Scholar
• Courtney C, Farrell D, Gray R et al. (2000 AD Collaborative Group). Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomized double-blind trial. Lancet 363, 2105–2115 (2004).
   PubMed Web of Science ®Google Scholar
• Bullock R. Galantamine: use in Alzheimer’s disease and related disorders. Expert Rev. Neurotherapeutics 4(2), 153–163 (2004).
   PubMedGoogle Scholar
• Olin J, Schneider L. Galantamine for Alzheimer’s disease (Cochrane review). In: The Cochrane Library, Issue 1 Update Software, Oxford, UK (2001).
   Google Scholar
• Reisberg B, Doody R, Stoffler A et al. Memantine in moderate-to-severe Alzheimer’s disease. N. Engl. J. Med. 348(14), 1333–1341 (2003).
   PubMed Web of Science ®Google Scholar
• Rive B, Vercelletto M, Damier FD et al. Memantine enhances autonomy in moderate to severe Alzheimer’s disease. Int. J. Geriatr. Psychiatry 19(5), 458–464 (2004).
   PubMedGoogle Scholar
• Tariot PN, Farlow MR, Grossberg GT et al. Memantine treatment in patients with moderate to severe Alzheimer’s disease already receiving donepezil: a randomized controlled trial. JAMA 291(3), 317–324 (2004).
   PubMed Web of Science ®Google Scholar
• Gandy S, Martins RN, Buxbaum J. Molecular and cellular basis for anti-amyloid therapy in Alzheimer’s disease. Alzheimer Dis. Assoc. Disord. 17(4), 259–266 (2003).
   PubMed Web of Science ®Google Scholar
• Tuszynski MH, Thal L, Pay M et al. A Phase I clinical trial of nerve growth factor gene therapy for Alzheimer’s disease. Nature Med. 11, 551–555 (2005).
   PubMed Web of Science ®Google Scholar
• Desai A, Grossberg G. Review of rivastigmine and its clinical applications in Alzheimer’s disease and related disorders. Exp. Opin. Pharmacother. 2(4), 653–666 (2001).
   PubMedGoogle Scholar
• Farlow MR. Update on rivastigmine. The Neurologist 9(2), 230–234 (2003).
   PubMed Web of Science ®Google Scholar
• Massoulie J, Bon S. The molecular forms of cholinesterase and acetylcholinesterase in vertebrates. Ann. Rev. Neurosci. 5, 57–106 (1982).
   PubMed Web of Science ®Google Scholar
• Andin J, Enz A, Gentsch C, Marcusson J. Rivastigmine as a modulator of the neuronal glutamate transporter rEAAC1 mRNA expression. Dement. Geriatr. Cogn. Disord. 19(1), 18–23 (2005).
   PubMedGoogle Scholar
• Tasker A, Perry EK, Ballard CG. Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment. Expert Rev. Neurotherapeutics 5(1), 101–106 (2005).
   PubMedGoogle Scholar
• Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR. Inhibition of acetyl- and butyrylcholinesterase in the cerebrospinal fluid of patients with Alzheimer’s disease by rivastigmine: correlation with cognitive benefit. J. Neural. Transm. 109(7–8), 1053–1065 (2002).
   PubMed Web of Science ®Google Scholar
• Mesulam MM, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyse acetylcholine. Neuroscience 110, 627–639 (2002).
   PubMed Web of Science ®Google Scholar
• Ballard C, Morris C, Kalaria R et al. The k variant of the butyrylcholinesterase gene is associated with reduced phosphorylation of tau in dementia patients. Dement. Geriatr. Cogn. Disord. 19, 357–360 (2005).
   PubMedGoogle Scholar
• Holmes C, Ballard C, Lehmann D et al. Rate of progression of cognitive decline in Alzheimer’s disease: effect of butyrylcholinesterase K gene variation. J. Neurol. Neurosurg. Psychiatry. 76, 640–643 (2005).
   PubMed Web of Science ®Google Scholar
• McGuire MC, Nogueira CP, Bartels CF et al. Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc. Natl. Acad. Sci. USA86, 953–957 (1989).
   PubMed Web of Science ®Google Scholar
• Darreh-Shori T, Almkvist O, Guan ZZ et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 59(4), 563–572 (2002).
   PubMedGoogle Scholar
• Lane RM, Kivipelto M, Grieg NH. Acetylcholinesterase and its inhibition in Alzheimer’s disease. Clin. Neuropharmacol. 27(3), 14–19 (2004).
   PubMedGoogle Scholar
• Polinsky RJ. Clinical pharmacology of rivastigmine: a new generatioin acetylChEI for the treatment of Alzheimer’s disease. Clin. Ther. 20, 634–647 (1998).
   PubMed Web of Science ®Google Scholar
• Bentue-Ferrer D, Tribut O, Polard E, Allain H. Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs. 17(13), 947–963 (2003).
   PubMedGoogle Scholar
• Grossberg GT, Stahelin HB, Messina JC, Anand R, Veach J. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int. J. Geriatr. Psychiatry 15, 242–247 (2000).
   PubMed Web of Science ®Google Scholar
• Alexopoulos GS, Jeste DV, Chung H, Carpenter D, Ross R, Docherty JP. Treatment of dementia and its behavioral disturbances. The Expert Consensus Guideline Series. Postgrad. Med. Special report. 1–22, (2005).
   Google Scholar
• Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartarate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int. J. Geriatr. Psychopharmacol. 1, 55–65 (1998).
   Google Scholar
• Rosler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomized controlled trial. Br. Med. J. 318, 633–638 (1999).
   PubMed Web of Science ®Google Scholar
• Cutler NR, Anand R, Hartman RD, Messina JC, Jhee SS. Anti-emetic therapy for Alzheimer’s patients receiving the cholinesterase inhibitor SDZ ENA 713. Clin. Pharmacol. Ther. 63, 188 (1998).
   Web of Science ®Google Scholar
• Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer’s disease (Cochrane review). In: The Cochrane Library (Issue 2). Update Software, Oxford, UK (2001).
   Google Scholar
• Morganroth J, Graham S, Hartman R, Anand R. Electrocardiographic effects of rivastigmine. J. Clin. Pharmacol. 42, 558–568 (2002).
   PubMed Web of Science ®Google Scholar
• Jann MW. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer’s disease. Pharmacotherapy 20, 1–11 (2000).
   PubMed Web of Science ®Google Scholar
• McKeith I, Del Ser T, Spano P et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet356(9247), 2031–2036 (2000).
   PubMed Web of Science ®Google Scholar
• Grace J, Daniel S, Stevens T et al. Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int. Psychogeriatr. 13(2), 199–205 (2001).
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson’s disease. N. Engl. J. Med. 351, 2509–2518 (2004).
   PubMed Web of Science ®Google Scholar
• McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34, 939–944 (1984).
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189–198 (1975).
   PubMed Web of Science ®Google Scholar
• Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am. J. Psychiatry. 141, 1356–1364 (1984).
   PubMed Web of Science ®Google Scholar
• Reisberg B, Schneider L, Doody R et al. Clinical global measures of dementia. Alzheimer Dis. Assoc. Disord. 11, 8–18 (1997).
   PubMed Web of Science ®Google Scholar
• Reisberg B, Ferris SH, De Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am. J. Psychiatry. 139, 1136–1139 (1982).
   PubMed Web of Science ®Google Scholar
• DeJong R, Osterlund OW, Roy GW. Measurement of quality-of-life changes in patients with Alzheimer’s disease. Clin. Ther.11, 545–554 (1989).
   PubMed Web of Science ®Google Scholar
• Desai AK, Grossberg GT, Sheth DN. Activities of daily living in patients with dementia. Clinical relevance, methods of assessment and effects of treatment. CNS Drugs. 18(13), 853–875 (2004).
   PubMed Web of Science ®Google Scholar
• Cummings JL. ChEIs. A new class of psychotropic compounds. Am. J. Psychiatry. 157, 4–15 (2000).
   PubMed Web of Science ®Google Scholar
• Rosler M, Retz W, Retz-Junginger P et al. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioral symptoms in Alzheimer’s disease. Behav. Neurol. 11, 211–216 (1998).
   PubMed Web of Science ®Google Scholar
• Suh DC, Arcona S, Thomas SK et al. Risk of antipsychotic drug use in patients with Alzheimer’s disease treated with rivastigmine. Drugs Aging 21(6), 395–403 (2004).
   PubMed Web of Science ®Google Scholar
• Verny M, Fremont P, Bourrin JC et al. Reduced psychotropic drug use in patients with Alzheimer’s disease receiving rivastigmine: results of the EXELAN study. J. Drug Assess. 34, 1–9 (2004).
   Google Scholar
• Farlow MR, Lilly ML; ENA 713 B352 Study Group. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer’s disease for up to 5 years. BMC Geriatr. 5(1), 3 (2005).
   PubMedGoogle Scholar
• Small GW, Kaufer D, Mendiondo MS, Quarg P, Spiefel R. Cognitive performance in Alzheimer’s disease patients receiving rivastigmine for up to 5 years. Int. J. Clin. Pract. 59(4), 473–477 (2005).
   PubMed Web of Science ®Google Scholar
• Kurz A, Farlow M, Quarg P, Spiegel R. Disease stage in Alzheimer’s disease and treatment effects of rivastigmine. Alzheimer Dis. Assoc. Disord. 18(3), 123–128 (2004).
   PubMed Web of Science ®Google Scholar
• Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects with moderately severe Alzheimer’s disease. Int. J. Geriatr. Psychiatry 19(3), 243–249 (2004).
   PubMed Web of Science ®Google Scholar
• Aupperle PM, Koumaras B, Chen M, Rabinowicz A, Mirski D. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer’s disease: results of a 52-week open-label study. Curr. Med. Res. Opin. 20(10), 1605–1612 (2004).
   PubMed Web of Science ®Google Scholar
• Finkel SI. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer’s disease. Clin. Ther. 26(7), 980–990 (2004).
   PubMed Web of Science ®Google Scholar
• Wood S, Cummings JL, Hsu MA et al. The use of the Neuropsychiatric Inventory in nursing home residents: characterization and measurement. Am. J. Geriatr. Psychiatry. 8, 75–83 (2000).
   PubMed Web of Science ®Google Scholar
• Cummings J, Anand R, Koumaras B, Hartman R. Behavioral benefits in Alzheimer’s disease patients residing in a nursing home following 52 weeks of treatment with rivastigmine. Poster presented at the 153rd annual meeting of the American Psychiatric Association, IL, USA. (13–18 May 2000).
   Google Scholar
• Ballard C, Margallo-Lana M, Juszczak E et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer’s disease: randomized double-blind placebo-controlled trial. Br. Med. J. 330, 874 (2005).
   PubMedGoogle Scholar
• Hatoum HT, Lin SJ, Arcona S, Thomas SK, Koumaras B, Mirski D. The use of the occupational disruptiveness scale of the neuropsychiatric inventory-nursing home version to measure the impact of rivastigmine on the disruptive behavior of nursing home residents with Alzheimer’s disease. J. Am. Med. Dir. Assoc. 6(4), 238–245 (2005).
   PubMedGoogle Scholar
• Kumar V, Anand R, Messina J et al. An efficacy and safety analysis of Exelon in Alzheimer’s disease with concurrent vascular risk factors. Eur. J. Neurol. 7, 159–169 (2000).
   PubMed Web of Science ®Google Scholar
• Farlow MR, Hake A, Messina J et al. Response of patients with Alzheimer’s disease to rivastigmine treatment is predicted by the rate of disease progression. Arch. Neurol. 58, 417–422 (2001).
   PubMed Web of Science ®Google Scholar
• Parkrasi S, Mukaetova-Ladinska EB, McKeith IG, O’Brien JT. Clinical predictors of response to acetylcholinesterase inhibitors: experience from routine clinical use in Newcastle. Int. J. Geriatr. Psychiatry 18(10), 879–886 (2003).
   PubMedGoogle Scholar
• Adler G, Brassen S, Chwalek K, Dieter B, Teufel M. Prediction of treatment response to rivastigmine in Alzheimer’s dementia. J. Neurol. Neurosurg. Psychiatry. 75(2), 292–294 (2004).
   PubMed Web of Science ®Google Scholar
• Visser PJ, Scheltens P, Pelgrim E, Verhey FR; Dutch ENA-NL-01 Study Group. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer’s disease patients. Dement. Geriatr. Cogn. Disord. 19(2–3), 126–133 (2005).
   PubMed Web of Science ®Google Scholar
• Farlow M, Lane R, Kudaravalli S, He Y. Differential qualitative responses to rivastigmine in APOE ε4 carriers and noncarriers. Pharmacogenomics J. 4, 332–335 (2004).
   PubMed Web of Science ®Google Scholar
• Wirths O, Multhaup G, Bayer TA. A modified β-amyloid hypothesis: intraneuronal accumulation of the β-amyloid peptide – the first step of a fatal cascade. J. Neurochem. 91(3), 513–520 (2004).
   PubMed Web of Science ®Google Scholar
• Francis PT, Nordberg A, Arnold SE. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer’s disease? Trends Pharmacol. Sci. 26(2), 104–111 (2005).
   PubMed Web of Science ®Google Scholar
• Lahiri DK, Rogers JT, Greig NH, Sambamurti K. Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. Curr. Pharm. Des. 10(25), 3111–3119 (2004).
   PubMed Web of Science ®Google Scholar
• Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, Mori E. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer’s disease? Am. J. Psychiatry. 162, 676–682 (2005).
   PubMed Web of Science ®Google Scholar
• Erkinjuntti T, Skoog I, Lane R, Andrews C. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. Int. J. Clin. Pract. 57(9), 756–760 (2003).
   PubMed Web of Science ®Google Scholar
• Farlow M, Potkin S, Koumaras B, Veach J, Mirski D. Analysis of outcome in retrieved dropout patients in a rivastigmine vs. placebo, 26-week, Alzheimer’s disease trial. Arch. Neurol. 60(6), 843–848 (2003).
   PubMed Web of Science ®Google Scholar
• Hogan DB, Goldlist B, Naglie G, Patterson C. Comparison studies of cholinesterase inhibitors for Alzheimer’s disease. Lancet Neurol. 3(10), 622–626 (2004).
   PubMed Web of Science ®Google Scholar
• Mauskopf JA, Paramore C, Lee WC, Snyder EH. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J. Manag. Care Pharm. 11(3), 231–251 (2005).
   PubMedGoogle Scholar
• Gauthier S, Emre M, Farlow MR, Bullock R, Grossberg GT, Potkin SG. Strategies for continued successful treatment of Alzheimer’s disease: switching cholinesterase inhibitors. Curr. Med. Res. Opin. 19(8), 707–714 (2003).
   PubMed Web of Science ®Google Scholar
• Auriacombe S, Pere JJ, Loria-Kanza Y, Vellas B. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease who failed to benefit from treatment with donepezil. Curr. Med. Res. Opin. 18, 129–138 (2002).
   PubMed Web of Science ®Google Scholar
• Sadowsky CH, Farlow MR, Atkinson L et al. Switching from donepezil to rivastigmine is well-tolerated: Results of an open-label safety and tolerability study. Prim Care Companion J. Clin. Psychiatry. 7(2), 43–48 (2005).
   Google Scholar
• Emre M. Switching cholinesterase inhibitors in patients with Alzheimer’s disease. Int. J. Clin. Pract. Suppl. 127, 64–72 (2002).
   Google Scholar
• Hendrie HC. Epidemiology of dementia and Alzheimer’s disease. Am. J. Geriatr. Psychiatry. 6, S3-S18 (1998).
   PubMedGoogle Scholar
• Holmes C, Cairns N, Lantos P et al. Validity of current clinical criteria for Alzheimer’s disease, vascular dementia and dementia with Lewy Bodies. Br. J. Psychiatry 174, 45–50 (1999).
   PubMed Web of Science ®Google Scholar
• Roman GC. Vascular dementia. Advances in nosology, diagnosis, treatment and prevention. Panminerva Med. 46, 207–215 (2004).
   PubMedGoogle Scholar
• Erkinjuntti T, Roman G, Gauthier S. Treatment of vascular dementia – evidence from clinical trials with cholinesterase inhibitors. J. Neurol. Sci. 226(1), 63–66 (2004).
   PubMedGoogle Scholar
• Moretti R, Torre P, Antonello RM, Cazzaro G, Bava A. Rivastigmine in vascular dementia. Expert Opin. Pharmacother. 5(6), 1399–1410 (2004).
   PubMed Web of Science ®Google Scholar
• Moretti R, TorreP, Antonello RM Cazzato G. Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up. Eur. J. Neurol. 8, 361–362 (2001).
   PubMed Web of Science ®Google Scholar
• Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in subcortical vascular dementia: an open 22-month study. J. Neurol. Sci. 203–204, 141–146 (2002).
   Google Scholar
• Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A. An open-label pilot study comparing rivastigmine and low-dose aspirin for the treatment of symptoms specific to patients with subcortical vascular dementia. Curr. Ther. Res. 63, 443–458 (2002).
   Web of Science ®Google Scholar
• Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. Am. J. Alzheimer Dis. Other Dement. 18, 265–272 (2003).
   PubMedGoogle Scholar
• Moretti R, Torre P, Antonello RM, Bava A, Cazzato G. Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month comparative study. Int. J. Clin. Prac. 5, 1399–1410 (2004).
   Google Scholar
• Craig D, Birks J. Rivastigmine for vascular cognitive impairment. Cochrane Database Syst. Rev. 2, CD004744 (2005).
   Google Scholar
• McKeith I, Mintzer J, Aarsland D et al. Dementia with Lewy bodies. Lancet Neurol. 3, 19–28 (2004).
   PubMed Web of Science ®Google Scholar
• Tiraboschi P, Hansen LA, Alford M et al. Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer’s disease. Arch. Gen. Psychiatry 59(10), 946–951 (2002).
   PubMed Web of Science ®Google Scholar
• Cummings JL, Mega M, Gray K et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44, 2308–2314 (1994).
   PubMed Web of Science ®Google Scholar
• Wesnes KA, McKeith I, Ferrara R et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomized placebo-controlled international study using the cognitive drug research computerized assessment system. Dement. Geriatr. Cogn. Disord. 13(3), 183–192 (2002).
   PubMed Web of Science ®Google Scholar
• McKeith IG, Wesnes KA, Perry E, Ferrara R. Hallucinations predict attentional improvements with rivastigmine in dementia with lewy bodies. Dement. Geriatr. Cogn. Disord. 18(1), 94–100 (2004).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson’s disease: an 8-year prospective study. Arch. Neurol 60, 387–392 (2003).
   PubMed Web of Science ®Google Scholar
• Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging 21(14), 931–937 (2004).
   PubMed Web of Science ®Google Scholar
• Prasher VP. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer’s disease in adults with Down’s syndrome: implications for the intellectual disability population. Int. J. Geriatr. Psychiatry 19(6), 509–515 (2004).
   PubMed Web of Science ®Google Scholar
• de Tommaso M, Specchio N, Sciruicchio V, Difruscolo O, Specchio LM. Effects of rivastigmine on motor and cognitive impairment in Huntington’s disease. Mov. Disord. 19(12), 1516–1518 (2004).
   PubMed Web of Science ®Google Scholar
• Parry AM, Scott RB, Palace J, Smith S, Matthews PM. Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain 126(12), 2750–2760 (2003).
   PubMed Web of Science ®Google Scholar
• Dautzenberg PL, Mulder LJ, Olde Rikkert MG, Wouters CJ, Loonen A. Delirium in elderly hospitalized patients: protective effects of chronic rivastigmine usage. Int. J. Geriatr. Psychiatry 19(7), 641–644 (2004).
   PubMed Web of Science ®Google Scholar
• Mendelsohn E, Rosenthal M, Bohiri Y, Werber E, Kotler M, Strous RD. Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behavior and activities of daily living. Int. Clin. Psychopharmacol. 19(6), 319–324 (2004).
   PubMed Web of Science ®Google Scholar
• Lenzi A, Maltinti E, Poggi E, Fabrizio L, Coli E. Effects of rivastigmine on cognitive functioning and quality of life in patients with schizophrenia. Clin. Neuropharmacol. 26(6), 317–321 (2003).
   PubMed Web of Science ®Google Scholar
• Chez MG, Aimonovitch M, Buchanan T, Mrazek S, Tremb RJ. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J. Child Neurol. 19(3), 165–169 (2004).
   PubMed Web of Science ®Google Scholar
• Marin D, Amaya K, Casciano R et al. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer’s disease. Int. Psychogeriatr. 15(4), 385–398 (2003).
   PubMed Web of Science ®Google Scholar
• Wimo A. Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer’s disease: a review with methodological considerations. Drugs Aging 21(5), 279–295 (2004).
   PubMed Web of Science ®Google Scholar
• Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J. Cholinesterase inhibitors used in the treatment of Alzheimer’s disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging 21(7), 453–478 (2004).
   PubMed Web of Science ®Google Scholar
• Winblad B, Jelic V. Long-term treatment of Alzheimer’s disease. Efficacy and safety of acetylcholinesterase inhibitors. Alzheimer Dis. Assoc. Disord.. 18(1), S2–S8 (2004).
   PubMedGoogle Scholar
• Rockwood K, Wallack M, Tallis R. The treatment of Alzheimer’s disease: success short of cure. Lancet Neurol. 2, 630–633 (2003).
   PubMedGoogle Scholar
• Quinn J, Moore M, Benson DF et al. A videotaped CIBIC for dementia patients: validity and reliability in a simulated clinical trial. Neurology 58, 433–437 (2002).
   PubMed Web of Science ®Google Scholar
• Clegg A, Bryant J, Nicholson T et al. Clinical and cost–effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer’s disease: a systematic review. Int. J. Technol. Assess. Health Care 18(3), 497–507 (2002).
   PubMedGoogle Scholar
• Lanctot KL, Herrmann N, Yau KK et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer’s disease: a meta-analysis. CMAJ 169(6), 557–564 (2003).
   PubMed Web of Science ®Google Scholar
• Beusterien KM, Thomas SK, Gause D et al. Impact of rivastigmine use on the risk of nursing home placement in a US sample. CNS Drugs 18(15), 1143–1148 (2004).
   PubMedGoogle Scholar
• Enz A, Gentsch C. Co-administration of memantine has no effect on the in vitro or in vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain. Neuropharmacology 47(3), 408–413 (2004).
   PubMed Web of Science ®Google Scholar
• Kamat SM, Taca AC Jr, Grossberg GT. Use of antidementia agents for Alzheimer’s disease: past, present, and future. Primary Psychiatry 11(8), 56–60 (2004).
   Google Scholar
• Bullock R, Denzig A. Cognitive performance in patients with Alzheimer’s disease receiving cholinesterase inhibitors for up to 5 years. Int. J. Clin. Pract.. 59, 817–822 (2005).
   PubMed Web of Science ®Google Scholar
• Moghul S, Wilkinson D. Use of acetylcholinesterase inhibitors in Alzheimer’s disease. Expert Rev. Neurotherapeutics 1(1), 61–69 (2001).
   PubMedGoogle Scholar
• Bullock R. Treatment of behavioral and psychiatric symptoms in dementia: implications of recent safety warnings. Curr. Med. Res. Opin. 21, 1–10 (2005).
   PubMed Web of Science ®Google Scholar
• Gauthier S. Current and future therapeutic strategies for Alzheimer’s disease and related dementias. Expert Rev. Neurotherapeutics 2(3), 277–278 (2002).
   PubMedGoogle Scholar